Affordable Access

deepdyve-link
Publisher Website

The need to manage the risk of thromboembolism in COVID-19 patients.

Authors
  • Khan, Inayat Hussain1
  • Savarimuthu, Sugeevan2
  • Leung, Marco Shiu Tsun1
  • Harky, Amer3
  • 1 Faculty of Medicine, St George's Hospital Medical School, London, United Kingdom. , (United Kingdom)
  • 2 Department of Medicine, Broomfield Hospital, Chelmsford, United Kingdom. , (United Kingdom)
  • 3 Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom. Electronic address: [email protected] , (United Kingdom)
Type
Published Article
Journal
Journal of vascular surgery
Publication Date
Sep 01, 2020
Volume
72
Issue
3
Pages
799–804
Identifiers
DOI: 10.1016/j.jvs.2020.05.015
PMID: 32417304
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

COVID-19 first appeared in Wuhan, Hubei Province, China, in December 2019. Thought to be of zoonotic origin, it has been named SARS-CoV-2 (COVID-19) and has spread rapidly. As of April 20, 2020, there have been >2.4 million cases recorded worldwide. The inflammatory process, cytokine storm, and lung injury that are associated with COVID-19 can put patients at an increased risk of thrombosis. The total incidence of thrombotic events in COVID-19 patients is currently uncertain. Those with more severe disease and with other risk factors, including increasing age, male sex, obesity, cancer, comorbidities, and intensive care unit admission, are at higher risk of these events. However, there is little international guidance on managing these risks in COVID-19 patients. In this paper, we explore the current evidence and theories surrounding thrombosis in these unique patients and reflect on experience from our center. Copyright © 2020 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times